EventHealthSeptember 9, 2026

ARPA-H invests $62.7M in AI bots for heart failure treatment

ARPA-H will commit $62.7 million to develop FDA-authorized AI agents that direct heart failure treatment, including assessing symptoms, prescribing drugs, and ordering lab tests. First-year awards total $33.7 million to Atman Health, UpDoc, Tempus AI, Stanford, Duke, and Kaiser Permanente.

1 source

More stories today

Open the live feed